StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) stock

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.51−0.05 (-3.51%)

Close on Nov 17, 2026Market cap $2.77MP/E –Yield –

NeuroSense Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

NeuroSense Therapeutics's enterprise value was $3.04M on Nov 11, 2026, against $28.61M a year earlier. Over the last 5 years it ranged from -$8.24M to $40.52M, with a median of $15.44M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$3.04M-83.4%
2025Dec 31, 2025$18.25M-10.8%
2024Dec 31, 2024$20.46M–
2023Dec 29, 2023-$6.99M-313.9%
2022Dec 30, 2022$3.27M–

More NeuroSense Therapeutics figures

See a number that looks wrong?